Dataa | Follow-up | Treatment | p-value*** | |
---|---|---|---|---|
Ginger extract | Loratadine | |||
Total RQLQ score | Week 0 | 2.98 (0.99) | 3.12 (1.12) | 0.547 |
Week 3 | 1.88 (0.96) ††† | 1.92 (1.17) ††† | 0.881 | |
Week 6 | 1.34 (0.95) ††† | 1.44 (1.06) ††† | 0.660 | |
Activity limitation | Week 0 | 3.95 (1.08) | 4.32 (0.99) | 0.119 |
Week 3 | 2.64 (1.31) ††† | 2.98 (1.41) ††† | 0.279 | |
Week 6 | 1.75 (1.27) ††† | 2.15 (1.36) ††† | 0.211 | |
Sleep problems | Week 0 | 3.00 (1.46) | 2.93 (1.58) | 0.827 |
Week 3 | 1.87 (1.32) ††† | 1.50 (1.22) ††† | 0.209 | |
Week 6 | 1.13 (1.23) ††† | 1.18 (1.24) ††† | 0.861 | |
Non-nose/eye symptoms | Week 0 | 2.82 (1.28) | 2.96 (1.44) | 0.653 |
Week 3 | 1.65 (1.01) ††† | 1.92 (1.40) †† | 0.339 | |
Week 6 | 1.30 (1.13) ††† | 1.37 (1.19) ††† | 0.819 | |
Practical problems | Week 0 | 3.07 (1.52) | 3.50 (1.55) | 0.210 |
Week 3 | 2.04 (1.34) †† | 2.17 (1.50) ††† | 0.713 | |
Week 6 | 1.57 (1.35) ††† | 1.59 (1.22) ††† | 0.946 | |
Nose symptoms | Week 0 | 3.48 (1.20) | 3.92 (1.38) | 0.129 |
Week 3 | 2.28 (1.30) ††† | 2.33 (1.33) †† | 0.864 | |
Week 6 | 1.67 (1.36) ††† | 1.96 (1.31) ††† | 0.379 | |
Eye symptoms | Week 0 | 2.39 (1.44) | 2.28 (1.81) | 0.772 |
Week 3 | 1.47 (1.44) ††† | 1.28 (1.50) ††† | 0.578 | |
Week 6 | 1.05 (1.16) ††† | 1.00 (1.28) ††† | 0.864 | |
Emotion | Week 0 | 2.32 (1.53) | 2.10 (1.54) | 0.537 |
Week 3 | 1.46 (1.22) ††† | 1.31(1.33) ††† | 0.627 | |
Week 6 | 0.94 (0.95) ††† | 0.96 (1.06) ††† | 0.948 |